Hutchison China MediTechの1年間の目標
Hutchison China MediTechの1年間の目標は何ですか。
Hutchison China MediTech Ltd.の1年間の目標はGBX316 +24.42%です。
1年間の目標の定義は何ですか。
1年目標は今から1年後の予測株価です。
One year target is an estimate of a stock price for a point in time equal to a year from the current date. The price level most often reflects the collective opinion of different analysts on where the stock will be trading a year from now. For an analyst to identify an individual estimate, they have to project what a company’s business will look like in a year, typically focusing on revenue and other significant factors. They also consider the willingness of investors to pay a certain price. While the average or median recommendation may be predictive and reflect the actual future value, the results are usually not extremely successful.
LSEのセクタHealth Careにおける1年間の目標の企業と比べるHutchison China MediTech
Hutchison China MediTechは何をしますか。
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Hutchison China MediTechと類似の1年間の目標
- Convenience Retail Asiaの1年間の目標はHKD$4 +612.96%です。
- Vascular Biogenics Ltdの1年間の目標は$4 +2,306.25%です。
- China Foodsの1年間の目標はHKD$4 +76.32%です。
- China Telecomの1年間の目標はHKD$4 +4.64%です。
- AMVIGの1年間の目標はHKD$4 -96.81%です。
- Huadian Power Internationalの1年間の目標はHKD$4 +22.35%です。
- Hutchison China MediTechの1年間の目標はGBX316 +24.42%です。
- Growthpoint Properties Australia Stapled Securitiesの1年間の目標はAUD$4 +49.04%です。
- IntegraGen SAの1年間の目標は€4 +578.26%です。
- Weebit Nanoの1年間の目標はAUD$4 +103.66%です。
- Genkyotex SAの1年間の目標は€4 +21.68%です。
- Asia Cement (China)の1年間の目標はHKD$5 +118.59%です。
- U.Sの1年間の目標は$4 +333.33%です。